B1 - Metastatic Pancreatic Neuroendocrine Tumors Have Decreased Somatostatin Expression and Increased Akt Signaling

Published in 2020 Listed under Basic Science

C. Tran, A. Scott, G. Li, S. Sherman, P.H. Ear, J. Howe

ABSTRACT ID: 104

B11 - Clinicopathological and Genomic Features in Patients With Head and Neck Neuroendocrine Carcinoma

Published in 2020 Listed under Applied Basic Science

A. Ohmoto, Y. Sato, Y. Fujiwara, N. Fukuda, X. Wang, T. Urasaki, N. Hayashi, Y. Sato, K.Nakano, M. Yunokawa, M. Ono, J. Tomomatsu, S. Takahashi

ABSTRACT ID: 101

B12 - Functional Genetic Screen to Identify Drivers of Pancreatic Neuroendocrine Tumor Pathogenesis

Published in 2020 Listed under Applied Basic Science

C.K. Maharjan, J. Riordan, C. Fedderson, E. Zhu, B. Darbro, A. Dupuy, D. Quelle

ABSTRACT ID: 132

B13 - Efficacy of Combined MEK and CDK Targeted Therapies for Pancreatic Neuroendocrine Tumors

Published in 2020 Listed under Applied Basic Science

U.S. Shaik Amjad, C. Kaemmer, M. Chandra, J. Kohlmeyer, G. D, W. S, R. Sheehy, L. Mr ,D. Meyerholz, G. Zamba, S. O'Dorisio, J. Dillon, A. Scott, E.P. Hein, J. Howe, C. Chandrasekharan, A. Bellizzi, L. Herring, L. Graves, B. Darbro, D. Quelle

ABSTRACT ID: 146

B14 - A Blood-Based Neuroendocrine Tumor Mrna Signature Identifies Residual Tumor and Accurately Predicts Recurrence After Surgery

Published in 2020 Listed under Applied Basic Science

I. Modlin, M. Falconi, P.L. Filosso, A. Frilling, A. Malczewska, M. Kidd, K. Oberg

ABSTRACT ID: 148

B15 - Mapping Anti-Angiogenic Proteome Associated With Black Raspberry Extract and Gallic Acid in Neuroendocrine Cancer

Published in 2020 Listed under Applied Basic Science

J. Mehrez, B. Gentile, N. Skill, T. Milosavljevic, E. Chouest, M. Maluccio, E. Woltering

ABSTRACT ID: 179

B16 - A Systematic Workflow to Identify Anti-cancer Drugs Targeting Small BowelNeuroendocrine Tumors and Neuroendocrine Carcinomas

Published in 2020 Listed under Applied Basic Science

P. H. Ear, C. Tran, G. Li, J. Egan, C. Lotenschtein, E. Abusada, J. Mudd, C. Kaemmer, A. Miller, C. Chan, C. Chandrasekharan, M. Wu, S. O'Dorisio, D. Quelle, A. Bellizzi, R. C. Fields, J. Howe

ABSTRACT ID: 196

B17 - Preclinical Evaluation of Radionuclide Therapy Targeting CXCR4 and Thioredoxin Reductase in Atypical Carcinoid and Neuroendocrine Carcinoma

Published in 2020 Listed under Applied Basic Science

D. Liu, M. Fath, C. Robles Planells, J. Ewald, D. Spitz, M. O'Dorisio

ABSTRACT ID: 198

B2 - Proteotranscriptomic Classification and Characterization of Pancreatic Neuroendocrine Neoplasms

Published in 2020 Listed under Basic Science

K. Yang, S. Kalloger, J. Aird, M. Lee, C. Rushton, S. Spencer Miko ,K. Mungall, A. Mungall, S. Colborne, R. Morin, J. Loree, M. Marra, D. Renouf, G. Morin, D. Schaeffer, S. Gorski

ABSTRACT ID: 105

B3 - Telotristat Ethyl Augments Cytotoxic Chemotherapy Response in Preclinical Tumor Models

Published in 2020 Listed under Basic Science

N. Awasthi, M. Schwarz, R. Schwarz

ABSTRACT ID: 120

B4 - Neuroendocrine Tumor Omic Gene Cluster Analysis Amplifies the Prognostic Accuracy of the NETest

Published in 2020 Listed under Basic Science

M. Kidd, A. Kitz, I. Drozdov, I. Modlin

ABSTRACT ID: 158

B5 - Exploring Plasma-Derived Exosomes (PDEs) as a Response Biomarker in Neuroendocrine Tumors (NETs)

Published in 2020 Listed under Basic Science

M. Gupta, O. Maguire, M. Bapardekar, K. Attwood, H. Minderman,
R. Iyer

ABSTRACT ID: 177

B6 - The Anti-Proliferative Effects of the Mycotoxin Verrucarin A on Neuroendocrine Tumor Cells

Published in 2020 Listed under Basic Science

J. Whitt, Z. Patel, R. Guenter, H. Chen, R. Jaskula-Sztul

ABSTRACT ID: 182

B7 - MAML3 Overexpression Increases Tumorgenicity in Several Neuroendocrine Tumor Types

Published in 2020

N. Alzofon, K. Koc, K. Panwell, N. Pozdeyev, C. Marshall, M. Albuja-
Cruz, C. Raeburn, K. Nathanson, D. Cohen, M. Wierman, K. Kiseljak-
Vassiliades, L. Fishbein

ABSTRACT ID: 187

B9 - 5-Azacitidine Inhibits Neuroendocrine Tumors via the Induction of Notch3 by theTransactivator BORIS

Published in 2020

R. Zheng-Pywell , J. Whitt, K. Hale, H. Chen, R. Jaskula-Sztul, J.B. Rose

ABSTRACT ID: 203

C1 - Preliminary Safety, PK/PD, and Antitumor Activity of XmAb18087, an SSTR2 x CD3 Bispecific Antibody, in Patients with Advanced Neuroendocrine Tumors

Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics

B. El-Rayes, S. Pant, V. Villalobos, A. Hendifar, W. Chow, B. Konda, M. Reilley, A. Benson, G. Fisher, J. Starr, J. Strosberg, D. Ahn, K. Perez, N. Raj, J. Eads, T. Hobday, S. Chollate, Y. Ding, C. Fleener, J. Shorr

ABSTRACT ID: 111

C10 - Treatment Outcomes of Well- Differentiated High-Grade Neuroendocrine Tumors

Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics

A. Liu, B. Ueberroth, P. McGarrah, S. Buckner Petty, A. Kendi, J. Starr, T. Hobday, T. Halfdanarson, M. Sonbol

ABSTRACT ID: 143

C11 - Comparative Analysis of Octreotide Long Acting Release (LAR) and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): A Single Institution Experience

Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics

S. Wu, P. Reta-Impey, N. Manivannan, S.H. Tirumani, P. Fu, S. Cao, S. Asa, A. Kardan, F. Liu, N. Avril, P. Wojtylak, R. Lee, D. Bajor, E. Selfridge, J. Saltzman, J. Hardacre, J. Ammori, J. Winter, A. Mohamed

C14 - Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms

Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics

T. Al-Toubah, E. Pelle, T. Valone, M. Haider, J. Strosberg

ABSTRACT ID: 157

C16 - Comparative Outcomes of Second Line Topoisomerase I Inhibitor- Containing Therapies on Extrapulmonary Neuroendocrine Carcinoma

Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics

H.-M. Yeung, K. Sreekrishnanilayam, C. Meeker, M. Deng, S. Agrawal, H. Abdullah, E. Ross, N. Vijayvergia

ABSTRACT ID: 162

C17 - The Clinical Impact of Serum Chromogranin-A in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS)

Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics

S. Wu, P. Reta-Impey, N. Manivannan, P. Fu, S. Cao, S. Asa, S.H. Tirumani, J. Davidson, A. Kardan, N. Avril, P. Wojtylak, D. Bajor, R. Lee, E. Selfridge, J. Saltzman, J. Ammori, J. Hardacre, J. Winter, A. Mohamed

ABSTRACT ID: 163

C18 - Avelumab in Unresectable/ Metastatic, Progressive, Grade 2-3 Neuroendocrine Neoplasms (NEN): Combined Results from NET-001 and NET-002 Trials

Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics

D. Chan, V. Rodriguez Freixinos, M. Doherty, K. Wasson, N. Iscoe, W. Raskin, J. Hallet, S. Myrehaug, C. Law, A. Thawer, K. Nguyen, S. Singh

ABSTRACT ID: 164

C19 - Urinary Neuroendocrine Neoplasms Treated in the “Modern Era”: A Multicenter Retrospective Review

Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics

B. Le, P. McGarrah, J. Whitman, A. Paciorek, N. Raj, D. Reidy-Lagunes, H. Hauser, T. Le, J. Del Rivero, A. Apolo, E. Bergsland, T. Halfdanarson

ABSTRACT ID: 185

C20 - Efficacy of Somatostatin Analog (SSA) Monotherapy for Well-Differentiated Grade 3 (G3) Gastroenteropancreatic Neuroendocrine Tumors (NETs)

Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics

P. McGarrah, A. Liu, T. Hobday, J. Starr, A. Kendi, R. Graham, T. Halfdanarson, M. Sonbol

ABSTRACT ID: 200

C21 - Efficacy and Safety of Peptide Receptor Radionuclide Therapy in Lung Neuroendocrine Tumors: A Multicentre Study

Published in 2020 Listed under Clinical-PRRT-Nuclear

A. Iravani, L. Zidan, K. Oleinikov, S. Ben-Haim, D. Gross, A. Meirovitz, O. Maimon, T. Akhurst, M. Michael, R. Hicks, S. Grozinsky-Glasberg, G. Kong

ABSTRACT ID: 15

C22 - Patient Travel Concerns After Treatment with Peptide Receptor Radionuclide Therapy (PRRT)

Published in 2020 Listed under Clinical-PRRT-Nuclear

A. Kendi, T. Halfdanarson, B. Naraev, D. Mercer, J. Underwood, J. Mailman

ABSTRACT ID: 36

C24 - A Clinical Score(CS) for Well- Differentiated Neuroendocrine Tumor(WD-NET) Patients(Pts) Undergoing Peptide Receptor Radionuclide Therapy(PRRT)

Published in 2020 Listed under Clinical-PRRT-Nuclear

S. Das, L. Du, A. Schad, S. Jain, A. Jessop, C. Shah, D. Eisner, D. Cardin, K. Ciombor, L. Goff, M. Bradshaw, D. Delbeke, M. Sandler, J. Berlin

ABSTRACT ID: 44

C26 - Safety of 177Lu DOTATATE in Patients with Advanced Neuroendocrine Tumors: Data from a US Expanded Access Program

Published in 2020 Listed under Clinical-PRRT-Nuclear

M. Allen-Auerbach, E. Wolin, V. Nassiri, P. Broberg, G. El-Haddad

ABSTRACT ID: 118

C27 - Re-Treatment with 177Lu-DOTATATE in Patients With Neuroendocrine Tumors: Multicenter Real-World Experience

Published in 2020 Listed under Clinical-PRRT-Nuclear

S. Navalkissoor, M. Essler, M. Caplin, W. Van Der Zwan, M. Wicharz, W. De Herder, P. Broberg, E. Krenning

ABSTRACT ID: 119

C28 - Supportive Management during PRRT for Symptomatic Pheochromocytomas or Paragangliomas

Published in 2020 Listed under Clinical-PRRT-Nuclear

E. Tsang, G. Funk, J. Leung, G. Kalish, H. Kennecke

ABSTRACT ID: 134

C3 - Patient-Reported Activity Impairment, Work Productivity Loss, and Carcinoid Syndrome Outcomes: Interim Analyses of the XERMELO Patient Registry

Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics

C. Darden, V. Joish, M. Price, D. Garbinsky, S. Schwartz, C. Warner, S. Wason, P. Lapuerta

ABSTRACT ID: 113

C30 - 64Cu-DOTATATE PET in Neuroendocrine Tumor Patients: What We Learned From the First 1,200 Patients

Published in 2020 Listed under Clinical-PRRT-Nuclear

A. Kjaer, E. Carlsen, M. Loft, C. Johnbeck, T. Binderup, S. Langer, B. Federspiel, U. Knigge

ABSTRACT ID: 147

C31 - PRRT Neuroendocrine Tumor Response Monitored Using Circulating Transcript Analysis: The NETest

Published in 2020 Listed under Clinical-PRRT-Nuclear

L. Bodei, M. Kidd, A. Singh, W. Van Der Zwan, S. Severi, I. Drozdov, A. Malczewska, G. Paganelli, E. Krenning, I. Modlin

ABSTRACT ID: 160

C32 - Dynamic Contrast-Enhanced CT to Evaluate Response in Neuroendocrine Liver Metastases Treated with Everolimus and Radiation

Published in 2020 Listed under Clinical-PRRT-Nuclear

J. Hudson, S. Singh, V. Rodriguez-Freixinos, D. Chan, J. Hallet, C. Law, S. Myrehaug

ABSTRACT ID: 165

C33 - Association Between Surveillance Imaging and Survival Outcomes in Small Bowel Neuroendocrine Tumors

Published in 2020 Listed under Clinical-PRRT-Nuclear

A. Watanabe, L. Yip, G. McKendry, J. Loree, H. Stuart

ABSTRACT ID: 167

C35 - Real-World Analysis of Safety and Tolerance of Repeat Peptide Receptor Radionuclide Therapy

Published in 2020 Listed under Clinical-PRRT-Nuclear

J. Chau, H. Bakeri, N. Yu, Y. Menda, J. Dillon, C. Chandrasekharan

ABSTRACT ID: 192

C36 - 212Pb-AlphaMedixTM Targeted Alpha Therapy (TAT): A Potential Breakthrough in Treatment of Metastatic SSTR Expressing NET

Published in 2020 Listed under Clinical-PRRT-Nuclear

E. Delpassand, I. Tworowska, J. Torgue, J. Hurt, R. Nuñez, R. Esfandiari

ABSTRACT ID: 193

C37 - Single Institution Experience With Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)

Published in 2020

H. Duan, V. Ferri, P. Kunz, G. Davidzon, J. Nguyen, F. Moradi, B. Franc, A. Iagaru, C. Aparici Mari

ABSTRACT ID: 194

C39 - Hematotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) – A Single Institution Experience

Published in 2020 Listed under Clinical-PRRT-Nuclear

H. Duan, V. Ferri, P. Kunz, G. Davidzon, F. Moradi, J. Nguyen, B. Franc, A. Iagaru, C. Aparici Mari

ABSTRACT ID: 199

C4 - Carcinoid Syndrome (CS) Improvements in Patients Receiving Telotristat Ethyl (TE): Findings from TELEPRO-II

Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics

M. Kulke, V. Di Gialleonardo, V. Joish, K. Murali, H. Kennecke

ABSTRACT ID: 115

C40 - Renal and Hepatotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) – A Single Institution Experience

Published in 2020 Listed under Clinical-PRRT-Nuclear

H. Duan, V. Ferri, P. Kunz, G. Davidzon, J. Nguyen, F. Moradi, B. Franc, A. Iagaru, C. Aparici Mari

ABSTRACT ID: 201

C41 - Preoperative Risk Stratification of Lymph Node Metastasis for Non-Functional Pancreatic Neuroendocrine Neoplasm: An International Dual-Institutional Study

Published in 2020 Listed under Clinical-Surgical-Applied_Pathology

Y. Kasai, T. Masui, E. Nakakura, K. Nakano, A. Sato, Y. Uchida, A. Yogo, K. Nagai, T. Anazawa, T. Hope, G. Kim, J. Whitman, B. Le, K. Takaori, E. Bergsland, S. Uemoto ABSTRACT ID: 12

C42 - Response Rates in Metastatic Neuroendocrine Tumors Receiving Peptide Receptor Radionuclide Therapy and Implications for Future Treatment Strategies

Published in 2020

T. Vaghaiwalla, B. Ruhle, K. Memeh, P. Angelos, E. Kaplan, B. Polite, C.-Y. Liao, X. Keutgen ABSTRACT ID: 13

C43 - Ultrasound-Guided Percutaneous Ethanol Ablation for Loco-Regional Recurrence of Medullary Thyroid Cancer

Published in 2020 Listed under Clinical-Surgical-Applied_Pathology

T. Szabo Yamashita, R. Rogers, M. Lyden, G. Thompson, T. Foster, J. Morris, T. McKenzie, B. Dy ABSTRACT ID: 46

C45 - It’s Time to Rethink Biomarkers for Surveillance of Small Bowel Neuroendocrine Tumors

Published in 2020 Listed under Clinical-Surgical-Applied_Pathology

C. Tran, S. Sherman, A. Scott, P.H. Ear, C. Chandrasekharan, A. Bellizzi, J. Dillon, T. O’Dorisio, J. Howe ABSTRACT ID: 103

C47 - Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems

Published in 2020 Listed under Clinical-Surgical-Applied_Pathology

H. Wachtel, T. Hutchens, E. Baraban, L. Schwartz, K. Montone, Z. Baloch, V. Livolsi, L. Krumeich, D. Fraker, K. Nathanson, D. Cohen, L. Fishbein ABSTRACT ID: 127

C48 - Metabolic Changes in Pheochromocytoma and Paraganglioma: Correlation Between Plasma Hormone Levels, Weight and Diabetes

Published in 2020 Listed under Clinical-Surgical-Applied_Pathology

L. Krumeich, A. Cucchiara, K. Nathanson, R. Kelz, L. Fishbein, D. Fraker, R. Roses, D. Cohen, H. Wachtel ABSTRACT ID: 128

C49 - Pattern of Disease Recurrence and Treatment after Surgery for Nonfunctioning Well- Differentiated Pancreatic Neuroendocrine Tumors (NF-PanNET)

Published in 2020 Listed under Clinical-Surgical-Applied_Pathology

V. Andreasi, S. Partelli, L. Landoni, C. Nessi, F. Muffatti, S. Crippa, S. Cingarlini, C. Bassi, M. Falconi ABSTRACT ID: 150

C50 - Socioeconomic Disparities in Midgut Neuroendocrine Tumors (MNETs): An NCDB Analysis

Published in 2020 Listed under Clinical-Surgical-Applied_Pathology

T. Diperi, N. Manguso, B. Cox, K. Atkins, A. Hendifar, J. Gong, A. Gangi ABSTRACT ID: 169

C52 - Upfront Interventional Treatments Prior to Liver-progression for Small Bowel Neuroendocrine Liver Metastasis

Published in 2020 Listed under Clinical-Surgical-Applied_Pathology

Y. Kasai, K. Hirose, C. Corvera, G. Kim, T. Hope, N. Fidelman, R. Warren, E. Bergsland, E. Nakakura ABSTRACT ID: 174

C54 - Survival After Resection of Poorly Differentiated Gastroenteropancreatic Neuroendocrine Neoplasm: Association of Nodal Involvement and Survival

Published in 2020 Listed under Clinical-Surgical-Applied_Pathology

L. Thornblade, L. Melstrom, S. Warner, P. Ituarte, S. Chang, D. Li, Y. Fong1 G. Singh ABSTRACT ID: 190

C6 - Efficacy of Checkpoint Inhibitors in Neuroendocrine Neoplasms: The Mayo Clinic Experience

Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics

J. Gile, A. Liu, P. McGarrah, R. Eiring, J. Starr, M. Sonbol, T. Hobday, T. Halfdanarson

ABSTRACT ID: 125

C8 - Lanreotide Autogel (LAN) 120 mg Every 14 Days in Progressive Pancreatic Neuroendocrine Tumors (panNETs): CLARINET FORTE Study

Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics

M. Pavel, J. Ćwikła, C. Lombard-Bohas, I. Borbath, T. Shah, U.-F. Pape, X.-M. Truong Thanh, A. Houchard, P. Ruszniewski

ABSTRACT ID: 135

C9 - Lanreotide Autogel (LAN) 120 mg Every 14 Days in Progressive Midgut Neuroendocrine Tumors (NETs): CLARINET FORTE Study

Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics

M. Pavel, J. Ćwikła, C. Lombard-Bohas, I. Borbath, T. Shah, U.-F. Pape, X.-M. Truong Thanh, A. Houchard, P. Ruszniewski

ABSTRACT ID: 136

O10 - The Use of Octreotide LAR in Routine Canadian Practice: Dosing Considerations and Persistence Rates

Published in 2020 Listed under Other

S. Singh, W. Cheung, H. Gourdeau

ABSTRACT ID: 178

O11 - Neuroendocrine Carcinoma of the Rectum & Anus: Patient Characteristics and Treatment Modalities

Published in 2020 Listed under Other

B. Ueberroth, A. Liu, T. Halfdanarson, M. Sonbol

ABSTRACT ID: 191

O2 - Development and Validation of the Disease-Specific QOL-CD Quality of Life Questionnaire for Patients with Cushing’s Disease

Published in 2020 Listed under Other

M. Cusimano, T. Huang, A. Marchie, H. Smyth, K. Kovacs

ABSTRACT ID: 108

O3 - Survey of Challenges in Access to Diagnostics and Treatment for Neuroendocrine Tumor (NET) Patients (SCAN) – USA and Canada vs Global Diagnosis of NETs

Published in 2020 Listed under Other

E. Gellerman, J. Herman, M. McDonnell, D. Van Genechten, M. Pavel, D. O'Toole, H. Singh, J. Chen, J. Howe, S. Singh, C. Bouvier, C. Rodien-Louw, S. Leyden, S. Dureja, T. Kolarova

ABSTRACT ID: 126

O4 - Identifying Care Processes Promoting Person-Centred Care for Patients Diagnosed With Neuroendocrine Tumours (NETs)

Published in 2020 Listed under Other

J. Hallet, V. Zuk, L. Moody, D. Chan, M. Michael, T. Halfdanarson, R. Pommier, S. Myrehaug, R. Goodwin, C. Law, J. Herman, S. Sohail, F. Wright, L. Gotlib Conn

ABSTRACT ID: 129

O5 - Supporting Accurate Patient Information for An Uncommon Malignancy: Evaluation of the Quality of Information on Neuroendocrine Tumors (NETs) on the Internet

Published in 2020 Listed under Other

S. Sohail, V. Zuk, T. Halfdanarson, D. Chan, S. Pattison, R. Vasdev, C. Law

ABSTRACT ID: 131

O7 - Stereotactic Ablative Radiotherapy for the Management of Neuroendocrine Liver Metastases

Published in 2020 Listed under Other

J. Hudson, H. Chung, W. Chu, A. Taggar, L. Davis, J. Hallet, C. Law, S. Singh, S. Myrehaug

ABSTRACT ID: 166

O8 - Role of Chromogranin A-derived Fragments as Biomarkers for Pancreatic Neuroendocrine Tumors (PanNET)

Published in 2020 Listed under Other

V. Andreasi, S. Partelli, M. Manzoni, B. Colombo, F. Muffatti, A. Corti, M. Falconi

ABSTRACT ID: 168

O9 - Patient Experience with Somatostatin Analog Treatments for Neuroendocrine Tumors: Insight from Qualitative Interviews

Published in 2020 Listed under Other

C. Seo, E. Horodniceanu, R. Shah, G. Goldstein, D. Ray, B. Bennett, A. Phan, K. McCarrier

ABSTRACT ID: 171

P1 - Cross-Sectional Study Assessing the Feasibility of Using NET VITALS Communication Tool Among Patients With Neuroendocrine Tumors

Published in 2020 Listed under Population Science

D. Li, G. Imbesi, L. Yen, H. Kim, C.L. Sun, R. Allen, M. Sedrak, G. Singh

ABSTRACT ID: 37

P11 - Intensive Personalized Program for Living with NENs as a Chronic Disease

Published in 2020 Listed under Population Science

M. Rosenberg, S. Glasberg, T. Whyand

ABSTRACT ID: 186

P2 - Trends in the Incidence and Survival Outcomes in Patients With Lung Neuroendocrine Neoplasms in the United States

Published in 2020 Listed under Population Science

S. Shah, R. Gosain, A. Groman, R. Gosain, A. Dasari, T. Halfdanarson, S. Mukherjee

ABSTRACT ID: 73

P3 - Upfront Small Bowel Resection for Small Bowel Neuroendocrine Tumors With Synchronous Metastases: A Propensity Matched Comparative Population-Based Analysis

Published in 2020 Listed under Population Science

S. Bennett, N. Coburn, C. Law, V. Zuk, A. Mahar, L. Davis, S. Singh, S. Myrehaug, V. Gupta, J. Levy, J. Hallet

ABSTRACT ID: 76

P4 - Mapping the Patient Journey to Neuroendocrine Tumor (NET) Diagnosis Using Real-World Data (RWD)

Published in 2020 Listed under Population Science

N. Zimmerman, D. Ray, N. Princic, M. Moynihan, C. Clarke, A. Phan

ABSTRACT ID: 98

P5 - Costs Associated with Misdiagnoses of Neuroendocrine Tumors (NET)

Published in 2020 Listed under Population Science

A. Phan, D. Ray, N. Princic, M. Moynihan, C. Clarke

ABSTRACT ID: 99

P6 - Real World Analysis of Misdiagnosis Among Patients with Neuroendocrine Tumors (NET)

Published in 2020 Listed under Population Science

C. Clarke, D. Ray, N. Princic, M. Moynihan, A. Phan

ABSTRACT ID: 100

P7 - Retrospective Analysis of DIPNECH and Carcinoid Tumorlets Progressing to Invasive Pulmonary Carcinoid Tumors

Published in 2020 Listed under Population Science

T.Y. Sun, A. Codima, G. Hwang, K. Hornbacker, D. Pancirer, N. Lui, R. Raj, P. Kunz, S. Padda

ABSTRACT ID: 140

P9 - Risk of Cancer-Specific Death for Patients Diagnosed With Neuroendocrine Tumors (NETs): A Population-Based Analysis

Published in 2020 Listed under Population Science

J. Hallet, V. Zuk, S. Singh, C. Law, A. Mahar, S. Myrehaug, H. Zhao, A. Assal, N. Coburn

ABSTRACT ID: 180

T1 - Circulating Tumor DNA (Ct DNA) as a Biomarker in High- Grade Gastroenteropancreatic Neuroendocrine Tumor

Published in 2020 Listed under Trials In Progress

S. Mukherjee, M. Choi, R. Ramirez, K. Attwood, R. Iyer

ABSTRACT ID: 116

T3 - Cabozantinib in High Grade Neuroendocrine Neoplasm

Published in 2020 Listed under Trials In Progress

N. Trikalinos, D. Chatterjee, C. Hammill, E. Lu, K. Pedersen, H. Park, R. Suresh, A. Wang-Gillam, K.-H. Lim, N. Bagegni, R.C. Fields, B. Tan, P. Grierson, O. Aranha, K. Winter, M. Amin

ABSTRACT ID: 161